Cargando…
Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
SIMPLE SUMMARY: Patients with metastatic triple-negative breast cancer (mTNBC) have a very poor prognosis. We assume that some mTNBC patients have worse treatment outcomes and defined them as cases of refractory TNBC. We tried to investigate the characteristics and treatment outcomes of our refracto...
Autores principales: | Kim, Hana, Kim, Hyo Jung, Kim, Hongsik, Kim, Hye Ryeon, Jo, Hyunji, Hong, Joohyun, Kim, Ryul, Kim, Ji-Yeon, Ahn, Jin Seok, Im, Young-Hyuck, Lee, Se Kyung, Kim, Haeyoung, Shin, Soo-Yong, Park, Yeon Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616548/ https://www.ncbi.nlm.nih.gov/pubmed/34830990 http://dx.doi.org/10.3390/cancers13225835 |
Ejemplares similares
-
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2021) -
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
por: Kim, Hongsik, et al.
Publicado: (2022) -
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
por: Kim, Hye Ryeon, et al.
Publicado: (2023) -
HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022) -
The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)